Company intelligence / Profile preview
Syndivia
Strasbourg, Grand Est, Francesyndivia.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Syndivia has developed the GeminiMab™ and DARx platforms for site-specific antibody-drug conjugation, enabling efficient and well-tolerated ADCs with optimal drug-to-antibody ratios. Their technology allows for unique DAR1, DAR2, and DAR4 hinge region site-specific ADCs. The company’s lead program SDV1001 has been outlicensed to Auricula Biosciences for clinical development targeting K-Ras malignancies. Another partnered program with Inatherys targeting CD71 entered Phase I/IIa clinical trials[1][2][5].
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Antibody–oligonucleotide conjugates (AOCs)Antibody–interleukin conjugates
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Auricula Biosciences (with TVM Capital & Eli Lilly)Inatherys[1]
Beyond the preview
Go deeper on Syndivia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syndivia.